Wall Street analysts expect that Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) will post earnings of ($0.13) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aptose Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.12). Aptose Biosciences reported earnings per share of ($0.17) during the same quarter last year, which would indicate a positive year-over-year growth rate of 23.5%. The business is expected to issue its next quarterly earnings results on Tuesday, March 10th.
According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.55) to ($0.51). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.63) per share, with EPS estimates ranging from ($0.70) to ($0.55). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Aptose Biosciences.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01.
APTO stock traded up $0.21 during midday trading on Thursday, reaching $3.75. 1,740,261 shares of the company were exchanged, compared to its average volume of 360,835. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.83 and a current ratio of 7.83. Aptose Biosciences has a 1-year low of $1.57 and a 1-year high of $3.97. The stock’s 50-day simple moving average is $2.43 and its 200 day simple moving average is $2.37. The company has a market cap of $190.33 million, a price-to-earnings ratio of -4.36 and a beta of 1.75.
Several institutional investors have recently made changes to their positions in the company. Man Group plc increased its holdings in shares of Aptose Biosciences by 8.6% in the 3rd quarter. Man Group plc now owns 1,609,424 shares of the biotechnology company’s stock valued at $3,356,000 after acquiring an additional 127,836 shares during the period. Creative Planning acquired a new position in shares of Aptose Biosciences in the 3rd quarter valued at $156,000. Sigma Planning Corp increased its holdings in shares of Aptose Biosciences by 4.1% in the 3rd quarter. Sigma Planning Corp now owns 228,150 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 9,000 shares during the period. P.A.W. Capital Corp acquired a new position in shares of Aptose Biosciences in the 3rd quarter valued at $1,043,000. Finally, Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Aptose Biosciences by 8.2% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 92,029 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 7,000 shares during the period. 25.61% of the stock is currently owned by institutional investors and hedge funds.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Article: Initial Coin Offerings entail a high degree of risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.